Summary of Clinical Use

Tildrakizumab completed Phase 3 clinical trial for plaque psoriasis (NCT01729754 and NCT01722331), and having shown significant clinical benefit over placebo and etanercept and a favourable safety profile [3], was EMA and FDA approved in 2018, for the treatment of phototherapy candidate, adult patients with moderate to severe plaque psoriasis.

Mechanism Of Action and Pharmacodynamic Effects

Tildrakizumab binds to and neutralises the activity of IL-23, a cytokine produced by dendritic cells and macrophages and a component of both the innate and adaptive immune systems. IL-23 is a heterodimer containing IL-23A (p19) and IL-12 p40 subunits. Tildrakizumab binds to IL-23A. This action reduces IL-23-mediated activation of Th17 cells, and inhibits their release of pro-inflammatory cytokines and chemokines.

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)